Wird geladen...

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

Metastatic castration resistant prostate cancer is one of the main causes of male cancer associated deaths worldwide. Development of resistance is inevitable in patients treated with anti-androgen therapies. This highlights a need for novel therapeutic strategies that would be aimed upstream of the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: McClurg, Urszula L., Azizyan, Mahsa, Dransfield, Daniel T., Namdev, Nivedita, Chit, Nay C.T.H., Nakjang, Sirintra, Robson, Craig N.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5982776/
https://ncbi.nlm.nih.gov/pubmed/29861848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25167
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!